Prasol Chemicals Ltd

Prasol Chemicals Ltd has announced that its Board of Directors will convene on November 2, 2026, to consider and approve the un-audited financial results for the quarter and half-year ended September 30, 2026. The meeting is scheduled to take place at the company's registered office in Navi Mumbai at 05:15 PM. The trading window, which was closed on September 28, 2026, will remain closed until 48 hours after the declaration of these financial results.

Prasol Chemicals Ltd has updated its Corporate Identification Number (CIN) and status with the Ministry of Corporate Affairs (MCA). The CIN has changed from U99999MH1992PLC065026 to L99999MH1992PLC065026, and its status has been updated from 'Unlisted' to 'Listed'. This change reflects the company's listing on the BSE and NSE.

Prasol Chemicals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Report from the Statutory Auditors. The meeting also noted the retirement of Dr. Chitra Vaidya, Vice-President – R&D, a Senior Managerial Personnel, effective September 30, 2026. The financial results were prepared in accordance with Indian Accounting Standards (IND AS).

Prasol Chemicals' first results since its September 16, 2026 listing show standalone revenue from operations of ₹433.6 Cr for Q1 FY27, up 35.7% year-on-year from ₹319.6 Cr and 29.5% sequentially from ₹334.9 Cr. Standalone PAT more than doubled YoY to ₹61.0 Cr (+150.7% from ₹24.3 Cr) and rose 207.3% QoQ from ₹19.9 Cr, with EPS of ₹10.52 against ₹4.20 a year ago. The print runs well ahead of the on-plan revenue range of ₹250–280 Cr and the 8–9% volume growth guidance flagged in our pre-result preview — a clear beat on both counts, though the company has published no formal quarterly guidance in the filing itself. Street coverage remains thin post-listing; no formal Q1 FY27 consensus estimates turned up in a search, consistent with the neutral, low-coverage posture flagged pre-result, so this print becomes the first real anchor for analyst models. Margin expansion is the bigger story than topline growth: net profit margin rose to 14.1% from 7.6% YoY (5.9% QoQ), and PBT margin to 19.3% from 10.3% YoY. Total expenses fell to 81.1% of revenue from operations from 90.0% a year ago. A meaningful share of that improvement traces to the 'changes in inventories' line, which swung from a ₹6.4 Cr drawdown a year ago to a ₹39.2 Cr net build this quarter — a roughly ₹45 Cr swing that mechanically reduces reported cost of goods sold when finished-goods/WIP stock is added rather than sold. Purchases of stock-in-trade also rose faster than revenue (20.1% of revenue vs 14.6% YoY), while employee costs and other expenses held broadly flat as a share of sales. Underlying margin quality should be read with the inventory build in mind rather than taken purely as pricing or cost-efficiency gains. The Board that approved these results also accepted the retirement of Dr. Chitra Vaidya, Vice-President – R&D (effective September 30, 2026), and closed the trading window ahead of Q2/H1 FY27 results — both routine disclosures alongside the results filing. Separately, the company reported an insider-trading violation on September 24, 2026, a governance flag worth tracking for resolution in coming filings, though it carries no read-through to this quarter's P&L. Management has issued no separate press release or commentary with this filing, so there is no company framing to reconcile against the numbers. Going into Q2 FY27, the key questions are whether the inventory-aided margin holds up once stock normalizes, and how EPS reads on the enlarged post-IPO share base after the September fresh issue of ~11.8 lakh shares. With the stock down ~7.8% from its ₹676 IPO price to ₹623.25 pre-result and only nascent analyst coverage, this result — a clear beat on the company's own on-plan revenue range and pre-IPO growth guidance — is likely to be the first data point consensus estimates get built around.

Prasol Chemicals Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut for all directors, KMPs, designated persons, and their relatives from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ending September 30, 2026. The specific date of the board meeting to consider these results will be communicated later. This measure is to prevent insider trading during the period leading up to the financial results announcement.

Prasol Chemicals Limited has reported a violation under SEBI (Prohibition of Insider Trading) Regulations, 2015. The violation pertains to the acquisition of 300 shares by Mr. Rahul Ashit Shroff, Chief Financial Officer and Finance Director, and deemed DP Mrs. Jamini Ashit Shroff, on September 18, 2026, for a value of Rs. 191,127. The shares were acquired during a trading window closure period. The company has issued a warning letter to the Designated Person, citing the insignificant trade value and inadvertent nature of the transaction. No previous instances of violations were reported, and no penalties were levied as the trade value was below Rs. 10 lacs per quarter.

Prasol Chemicals Ltd has announced that its Board of Directors will convene on September 28, 2026, at its registered office in Navi Mumbai. The primary agenda for this meeting is to consider and approve the un-audited financial results for the quarter ended June 30, 2026, along with the limited review report. The company has also informed that the trading window, which was closed on September 16, 2026, will remain shut until 48 hours after the declaration of these financial results.

Prasol Chemicals Ltd has informed the stock exchanges that its Board of Directors has authorized seven Key Managerial Personnel to determine the materiality of events and information and to make disclosures to the stock exchanges as per SEBI LODR Regulations. This authorization empowers these individuals to manage the company's regulatory disclosure obligations effectively. The authorized personnel include the Chairman, Managing Directors, Whole-time Directors, Chief Financial Officer, and Company Secretary. Their contact details have been provided and are also available on the company's website.

Prasol Chemicals Ltd has submitted an intimation under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. This filing includes the company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, framed under Regulation 8(1) of the same regulations. The company has made this information accessible on its official website, www.prasolchem.com, for public viewing and record.

Prasol Chemicals Limited has appointed Kfin Technologies Limited as its Registrar & Share Transfer Agent (RTA). This appointment ensures compliance with Regulation 7(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kfin Technologies will continue to serve as the RTA for the company. The company has also made this information accessible on its website, www.prasolchem.com, for public record and dissemination.